US equities |
NVDA $239.09 ▲+0.08% MU $1,048.42 ▼-1.46% SPCX $172.99 ▲+1.11% MRVL $285.39 ▲+5.21% AMD $650.83 ▲+3.02% INTC $113.41 ▼-2.40% AVGO $378.06 ▲+4.29% SNDK $1,657.31 ▼-2.75%
FinancialContent

DBV Technologies S.A. - American Depositary Shares (NQ:DBVT)

9.910 -0.530 (-5.08%)
Delayed Quote Updated: 3:42 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DBV Technologies S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in Upcoming September Investor Conferences
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Q2 Earnings Call Highlights ↗
DBV Technologies (NASDAQ:DBVT) said it is continuing preparations for a planned third-quarter 2026 Biologics License Application submission for its VIASKIN Peanut Patch in children ages 4 through 7,... 
Via MarketBeat
Topics Earnings
News headline image
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces the Results of its 2026 Combined General Meeting
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Combined General Meeting of June 3, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Reports First Quarter 2026 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Reports Full Year 2025 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in Upcoming March Investor Conferences
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
From DBV Technologies S.A.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >